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Despite advances in promoting axonal regeneration
after acute spinal cord injury (SCI), elicitation of
bridging axon regeneration after chronic SCI remains
a formidable challenge. We report that combinatorial
therapies administered 6 weeks, and as long as 15
months, after SCI promote axonal regeneration into
and beyond a midcervical lesion site. Provision of
peripheral nerve conditioning lesions, grafts of
marrow stromal cells, and establishment of NT-3
gradients supports bridging regeneration. Controls
receiving partial components of the full combination
fail to exhibit bridging. Notably, intraneuronal molec-
ular mechanisms recruited by delayed therapies
mirror those of acute injury, including activation of
transcriptional activators and regeneration-associ-
ated genes. Collectively, these findings provide
evidence that regeneration is achievable at unprece-
dented postinjury time points.
INTRODUCTION
Injured axons fail to spontaneously regenerate in either acute or
chronic stages of spinal cord injury (SCI), resulting in persistent
functional loss. Knowledge gained over the last several years
indicates that the failure of axonal regeneration after CNS injury
is attributable at least in part to (1) an absence of permissive
substrates to support axonal attachment and extension through
lesion sites (Bunge, 2001), (2) a lack of neurotrophic stimulation
(Jones et al., 2001), (3) myelin-based (Filbin, 2003) and extracel-
lular matrix inhibitors in the injured region (Fawcett, 2006), (4)
partial deficiency in the intrinsic growth capacity of adult neurons
(Neumann et al., 2002; Qiu et al., 2002), and (5) extensive
secondary damage resulting from inflammatory mechanisms
(Jones et al., 2005). Chronic SCI presents additional obstacles:
(1) glial scars and inhibitory extracellular matrices become well-established around the lesion site (Busch and Silver, 2007),
a mechanism that is thought to increase the refractory nature of
the chronically injured spinal cord to regeneration; (2) chronically
injured neurons downregulate regeneration-associated genes
and become atrophic (Kwon et al., 2002); (3) injured axons exhibit
varyingdegrees of retraction and retrogradedegeneration (Pallini
et al., 1988); and (4) progressive anterograde degeneration in
white matter beyond lesion sites potentially generates a particu-
larly refractory milieu for axonal extension (Houle and Tessler,
2003). Collectively, these mechanisms constitute formidable
barriers to regeneration in the chronically injured state.
Recent studies indicate that experimental strategies targeting
multiple mechanisms that limit adult CNS plasticity and regener-
ation may be capable of eliciting axonal regeneration into and
beyond sites of CNS injury, when administered immediately after
injury (Lu et al., 2004; Pearse et al., 2004; Houle et al., 2006).
These mechanisms include trophic factor availability (Lu et al.,
2004), the provision of permissive cellular or extracellular
matrices within injury sites (Lu et al., 2004; Pearse et al., 2004;
Houle et al., 2006), and augmentation of the intrinsic growth state
of the neuron by preconditioning lesions (pre-CL) or cAMP
administration (Lu et al., 2004; Pearse et al., 2004). We hypothe-
sized that combinatorial therapies administered at prolonged
time points after SCI would exhibit persistent effects in eliciting
the expression of regeneration-associated genes, thereby en-
hancing the intrinsic growth capacity of sensory neurons, and
when combined with delayed application of neurotrophic factors
beyond the lesion site,would be sufficient to elicit bridging axonal
regeneration. We now report successful bridging regeneration of
adult CNS axons when treatment is initiated from 6 weeks to as
long as 15months after the original injury, generated bymodifica-
tion of both cell-extrinsic and cell-intrinsic growth mechanisms.
RESULTS
Combinatorial Treatments Promote Bridging Axonal
Regeneration When Administered 6 Weeks after SCI
We initially examined whether combinatorial therapies would
promote bridging sensory axonal regeneration when treatmentNeuron 64, 165–172, October 29, 2009 ª2009 Elsevier Inc. 165
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Regeneration of Chronically Injured Axonswas delayed 6 weeks after SCI. A total of 51 adult Fischer 344
rats underwent C3 spinal cord dorsal column wire knife lesions
(Lu et al., 2004; Taylor et al., 2006). Six weeks later, combinato-
rial therapies were applied consisting of (1) a peripheral CL
(sciatic nerve crush bilaterally) to upregulate neuron-intrinsic
regeneration-associated gene expression (Neumann and Woolf,
1999); (2) placement of a syngenic bone marrow stromal cell
(MSC) graft mixed with 1 mg neurotrophin-3 (NT-3) protein in
the established C3 cystic lesion cavity, 1 week after CL (7 weeks
after the initial SCI) (Lu et al., 2004); and (3) provision of a neuro-
trophic factor gradient by injection of lentivirus expressing NT-3
into dorsal column white matter (Taylor et al., 2006), 2.5 mm
rostral to the lesion site, 1 week after CL (7 weeks after the initial
SCI, n = 16 animals; Figure 1A). In addition, four control groups
were examined: (1) nine subjects received C3 lesions, CL 6
weeks later, and a cell graft in the lesion site an additional
week later; neither NT-3 protein nor vector were administered;
(2) nine subjects received C3 lesions, a CL 6 weeks later, then
a cell graft mixed with 1 mg NT-3 protein in the lesion site and
lentivirus expressing the reporter gene Green Fluorescent
Figure 1. Sensory Axons Regenerate beyond the Lesion
Site When Treatments Influencing Both Neuron-Intrinsic
and Environmental Mechanisms Are Applied 6 Weeks
after the Original SCI
(A) Injury model and delayed combination therapy. Dorsal column
sensory axons were completely transected at C3. Six weeks or
fifteen months later, L4–6 DRG neurons were conditioned by
sciatic nerve crush. One week later, MSCs were injected into the
lesion site, and NT-3-expressing lentivirus was injected 2.5 mm
rostral to the lesion site. Animals survived an additional 6 weeks.
(B) Low-magnification sagittal overview from subject that received
delayed combination therapy. CTB-labeled dorsal column
sensory axons are evident approaching lesion/graft site on upper
right side of panel. Rostral, left; caudal, right. g, graft; h, host; IS,
lenti-NT-3 injection site 2.5 mm rostral to lesion border; dashed
lines, host/graft interface. Scale bar, 200 mm. Areas of higher
magnification are indicated in boxed regions. (C) Higher magnifi-
cation of graft: axons indicated by arrows course through graft
in irregular trajectories; several axons cross rostral interface with
host (dashed line in box C) to enter host spinal cord beyond the
lesion. (D) High magnification of (C) at interface of graft border
with host beyond the lesion, demonstrating sensory axons
crossing the interface. Notably, axons cross at several dorsoven-
tral levels of the host/graft interface, not simply at the most dorsal
or ventral aspects of grafts where spared axonsmight bemistaken
for regenerating axons. (E) Several varicose axons continue to
extend 500 mm beyond lesion site in host white matter. (F and G)
2 mm and 2.5 mm beyond the lesion, respectively, bridging axons
remain visible in host white matter. Lesion completeness was
confirmed by sectioning medulla, showing absence of CTB
labeling (Figure S1). Scale bar in (C), 40 mm; in (D)–(G), 20 mm.
Protein (GFP) into the dorsal white matter 2.5 mm
beyond the lesion an additional week later, while
NT-3 beyond the lesion was not provided; (3) eight
subjects underwent C3 lesions, no CL, and delivery
of 1 mg NT-3 protein into a cell graft in the lesion site
plus lenti-NT-3 vector 7 weeks after the initial injury;
and (4) nine subjects underwent C3 lesions and a cell
graft 7 weeks after the initial injury. Of note, chronic
scars surrounding the cystic lesion cavity were not resected in
any case, to avoid damage to the surrounding spinal cord (Tus-
zynski et al., 2003); thus, bridging axonal regeneration in this
paradigm would require growth into and beyond the perilesion
scar. An additional 6 weeks later, or 13 weeks after the original
C3 lesion, dorsal column sensory axons were traced transgan-
glionically by injections of cholera toxin B (CTB) subunit into
the sciatic nerve, and animals were sacrificed 3 days later.
Notably, axonal bridging beyond the lesion occurred only in
animals that received combinatorial treatment with CLs, MSC
grafts in the lesion cavity, and lenti-NT-3 injections (Figures 1
and 2). Ten out of sixteen animals in the full treatment group
exhibited axonal bridging beyond the lesion site; in the six re-
maining animals, lenti-NT-3 failed to diffuse from the rostral
injection site to the host/graft interface (Figure S1 available on-
line), and no axonal bridging was observed in these subjects.
In subjects with complete vector diffusion from the injection
site to the graft in the lesion cavity, axons extended in several
instances the full 2.5 mm distance beyond the lesion to the
rostral site of lenti-NT-3 injection. Further, growth occurred166 Neuron 64, 165–172, October 29, 2009 ª2009 Elsevier Inc.
Neuron
Regeneration of Chronically Injured AxonsFigure 2. Penetration of Lesion Site and
Quantification of Regeneration
Sagittal sections of C3 lesion/graft site, 3 months
after original injury. Rostral, left; caudal, right. (A)
Subjects treated only with MSC grafts demon-
strate rare penetration of CTB-labeled sensory
axons into graft, and no bridging. g, graft; h,
host. Lines indicate host/graft interface. (B) Injec-
tion of lenti-NT-3 vector beyond lesion site, and
NT-3 protein into MSC graft in lesion site, results
in slightly enhanced axon penetration of graft but
no axonal bridging beyond graft. (C and D) CLs
significantly enhance axon penetration into graft,
but axons rarely extend beyond the lesion, and
never for distances greater than 100 mm. (D)
Higher magnification of (C), showing axonal entry
into graft from caudal host/graft interface. (E and
F) Treatment with CL and NT-3 protein within
MSC graft, and lenti-GFP injection beyond, fails
to support axonal bridging beyond that observed
with CL alone. (F) Higher magnification of (E),
showing axonal entry into graft from caudal host/
graft interface. (G and H) As noted in Figure 1,
combinatorial treatment with CL and NT-3 gradi-
ents beyond the lesion support axon entry into
graft and significant axonal bridging beyond
lesion. (H) Higher magnification of (G), showing
axonal entry into graft. (I) Quantification of regen-
eration beyond lesion/graft site. Animals that
received CLs plus NT-3 gradients exhibit signifi-
cantly more sensory axons regenerating up to 500 mm beyond the lesion (Kruskall Wallis test, c2 p < 0.03; Dunn post hoc tests with Bonferroni correction p <
0.005). (J) Similarly, quantification of longest-bridging axon per subject demonstrates significant effects of combinatorial treatments (Kruskall Wallis test, c2
p < 0.01; Dunn post hoc with Bonferroni correction p < 0.005). (K) Quantification of axon number within graft demonstrates greatest growth into grafts in subjects
receiving CLs and NT-3 (ANOVA p < 0.0001; post hoc Fisher’s *p < 0.005 compared to all groups). Subjects that received CLs with or without single injections of
NT-3 protein in the graft also showed greater axon penetration than subjects with grafts only (post hoc Fisher’s **p < 0.05 in both cases). Scale bar in (A), (B), (C),
(E), and (G), 100 mm; in (D), (F), and (H), 50 mm. Data are shown as mean ± SEM.through host white matter undergoing Wallerian degeneration.
The morphology of extending axons was not typical of intact
axons: circuitous trajectories and frequent swellings of axons
were evident (Figures 1 and 2). Lesions were complete,
confirmed by absence of CTB label in the nucleus gracilis of all
subjects (Figure S1). Thus, regeneration of axons into and
beyond the lesion site in combination-treated animals was not
an artifact of axon sparing.
Axon quantification beyond the lesion revealed significantly
greater regeneration in combination-treated subjects compared
to all other groups (c2 p < 0.03; Dunn post hoc with Bonferroni
correction, p < 0.005; Figure 2I). Similarly, the maximum distance
of axonal regeneration was significantly greater in animals
receiving combination treatment (c2 p < 0.01; Dunn post hoc
with Bonferroni correction, p < 0.005; Figure 2J). Among controls,
axon growth beyond the lesion was detectable only among
subjects that received MSC grafts plus CLs, and only for very
short distances of 100 mm or less (Figure 2I). Unlike findings in
models of acute SCI (Taylor et al., 2006), treatment with MSC
graftsplus lenti-NT-3, in theabsenceof aCL, failed toelicit detect-
able axon extension for even short distances beyond the lesion
(Figure 2I). On the other hand, CLs with or without NT-3 protein
in the graft significantly increased penetration of sensory axons
into MSC grafts in the lesion cavity, relative to non-CL controls
(ANOVA p < 0.0001; post hoc Fisher’s p < 0.05; Figure 2K).Combinatorial Treatments Promote Bridging Axonal
Regeneration When Administered More Than 1 Year
after SCI
Next, we determined whether the same combinatorial therapies
would promote bridging axonal regeneration when administered
15months after SCI. Twenty-seven adult Fischer 344 rats under-
went C3 dorsal column lesions as described above. Fifteen
months later, subjects underwent bilateral CLs of the sciatic
nerve. One week later, the chronic lesion site was re-exposed,
and syngenic MSCs were grafted into the chronic lesion cavity
and lenti-NT-3 was injected 2.5 mm rostral to the lesion site
(n = 11 animals). In addition to this ‘‘full treatment’’ group, the
following controls were examined. (1) Four subjects received
MSC grafts, no CL, and injection of lenti-GFP 2.5 mm rostral to
the lesion (i.e., no NT-3 gradient); (2) six subjects received
MSC grafts, no CL, and injection of lenti-NT-3 2.5 mm rostral
to the lesion; and (3) six subjects received MSC grafts, CLs,
and lenti-GFP 2.5 mm rostral to the lesion.
Of note, regeneration beyond the lesion was observed in full
combination treatment animals when treatment was initiated
15 months after the original lesion (Figure 3). Five out of eleven
animals in the full treatment group exhibited axonal bridging
beyond the lesion site; in two out of the six remaining animals,
lenti-NT-3 vector failed to diffuse from the rostral injection site
to the host/graft interface (Figure S1); in one out of the sixNeuron 64, 165–172, October 29, 2009 ª2009 Elsevier Inc. 167
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Regeneration of Chronically Injured Axonsremaining animals, the graft did not survive. CTB immunolabel-
ing demonstrated dorsal column sensory axons first penetrating,
and then emerging from, the graft/host interface and extending
into rostral host white matter. Axons exhibited varicose mor-
phology with frequent swellings, and circuitous trajectories,
unlike spared axons (Figures 3 and 4). Further indicating that
these were not spared axons, medullary sectioning confirmed
absence of CTB labeling (Figure S1). Triple labeling for CTB,
GFP, and GFAP demonstrated that regenerating axons passed
Figure 3. Fifteen-Months-Delayed Combinatorial Treatment with
CLs, NT-3 Gradients, and MSC Graft in Lesion Site Promotes
Sensory Axonal Bridging in Chronic SCI
(A) Low-magnification sagittal overview. CTB-labeled sensory axons are
evident approaching lesion/graft site on upper right side of panel. Rostral,
left; caudal, right. g, graft; h, host; IS, lenti-NT-3 injection site, 2.5 mm rostral
to lesion; dashed lines, graft/lesion border. Scale bar, 300 mm. (B) Higher
magnification of graft/lesion region. CTB-labeled sensory axons enter graft
(box in D) and extend beyond graft into host spinal cord rostral to lesion
(box in E). (D and E) Higher magnification of (B), including caudal (D) and rostral
(E) interface of graft with host. Sensory axons cross host/graft interface at
several dorsoventral levels. (C) High magnification of (A): arrowheads indicate
a varicose axon extending 1200 mm beyond lesion site in host white matter. (F)
High magnification of (C). Arrowheads indicate a regenerating, varicose axon.
(G) High magnification of (A) demonstrates a regenerating axon 2200 mm
beyond lesion site in host white matter, extending in close association with
blood vessel wall. All lesions were complete, indicated by sectioning of
medulla (Figure S1). Scale bar in (B) and (C), 50 mm; (D) and (E), 20 mm; (F),
20 mm; and (G), 25 mm.168 Neuron 64, 165–172, October 29, 2009 ª2009 Elsevier Inc.through the GFAP immunoreactive border within the lesion site
and beyond into host white matter. Notably, axons regenerating
in host white matter were invariably associated with regions of
lenti-NT-3 expression, indicated by coassociation of axons
with the reporter gene GFP (Figures 4A–4F). As noted above,
the perilesion scar was not resected following the original lesion
to avoid further damage to the spinal cord. Control groups lack-
ing the combination treatment did not exhibit axonal bridging
(Figures 4G–4I).
Quantification of axon number beyond the lesion revealed
significantly greater regeneration in combination-treated sub-
jects compared to all other groups (c2 p < 0.003; Dunn post
hoc with Bonferroni correction, p < 0.008; Figure 4J). Similarly,
the maximum distance of axonal regeneration was significantly
greater in animals receiving combinatorial treatment (c2 p <
0.003; post hoc p < 0.008; Figure 4K). Groups treated with CLs
alone, or lenti-NT-3 injections alone, exhibited few sensory
axons regenerating into grafts and no regeneration beyond the
lesion (Figures 4J–4L). Thus, axons emerged from the graft and
regenerated beyond only when treatments modified both the
lesioned environment and the intrinsic state of neuronal activa-
tion.
DelayedConditioning Lesions IncreaseNeuron-Intrinsic
Growth Programs
To investigate intrinsic neuronal mechanisms related to
enhanced axonal regeneration at prolonged times after SCI,
we examined the expression of neuronal growth programs.
This is particularly important as a previous study reported that
CLs must be applied before SCI to promote regeneration (Neu-
mann and Woolf, 1999). We performed both in vitro assays
and gene array analyses. For in vitro studies, adult rats under-
went C3 dorsal column lesions, and 6 weeks later sciatic nerves
were crushed. One week later, sensory neurons of lumbar dorsal
root ganglia (DRG) L4–6 were cultured on myelin substrates for
48 hr. Neurite outgrowth was compared to sensory neurons
obtained from (1) intact subjects, (2) animals that underwent
C3 lesions 6 weeks earlier, without subsequent CLs, and
(3) animals that underwent CLs only, 1 week prior to explant.
As previously described, sensory neurons from animals that
underwent CL only (no central lesion) exhibited longer neurites
when compared to neurons from intact rats (p < 0.0001
ANOVA; p < 0.0001 post hoc Fisher’s; Figure 5E) (Smith and
Skene, 1997). Sensory neurons from animals that underwent
CLs 6 weeks after a C3 lesion also exhibited enhanced neurite
outgrowth compared to neurons from intact rats (p < 0.0001
post hoc Fisher’s; Figure 5E) that was equal in degree to that of
animals that underwent CLs alone (Figure 5E). In contrast, central
lesions alone, without a CL, did not enhance outgrowth (p = 0.54
post hoc Fisher’s). Thus, growth of injured sensory neurons can
be enhanced by CLs applied even 6 weeks after central injury.
Next, we examined expression of the regeneration-associated
genes GAP43 and c-Jun in DRG neurons (Raivich et al., 2004).
A 4-fold increase in the number of neurons labeled for GAP43
and c-Jun protein was observedwhenCLswere applied 6weeks
after C3 injury as compared to intact DRGs (p < 0.01 ANOVA;
p < 0.01 post hoc Fisher’s), equal to increases observed when
CLs were applied without a central lesion (Figures 5G–5P). C3
Neuron
Regeneration of Chronically Injured AxonsFigure 4. Only Subjects Undergoing Stimulation of
Both the Chronically Injured Neuron and the
Lesioned Environment Exhibit Significant Axonal
Bridging When Treatment Is Initiated 15 Months
after SCI
(A–F) Sagittal sections of C3 lesion/graft site, 16.5 months
after the original injury, triple labeled for CTB (A and B),
GFAP (C and D), and GFP (E and F) (rostral, left; caudal,
right) in subjects that received CLs, cell grafts, and NT-3
vector injections beyond the lesion site 15 months after
the original injury. (A and B) CTB-labeled sensory axons
extend into and then (B) emerge from the lesion site. (C
and D) GFAP labeling outlines the lesion border; regener-
ating axons extend into and beyond the GFAP-reactive
lesion boundary. (E and F) GFP labeling indicates exten-
sion of the lenti-NT-3 trophic gradient from the site of
vector injection to the immediate host/graft interface:
axons bridged beyond the lesion site only when lenti-
NT-3 vector spread to the lesion/graft boundary (see
Figure S1). CTB-labeled sensory axons penetrated grafts,
but did not bridge beyond the lesion site, in subjects
treated with (G) cell grafts alone, (H) lenti-NT-3 gradients
and cell grafts but no CL, or (I) CLs and cell grafts, but
no NT-3 gradient. (J) Quantification of axon growth
beyond lesion/graft site. Only animals that received full
treatment exhibited sensory axonal regeneration beyond
the lesion site. (Kruskall Wallis test, c2 p < 0.003; Dunn
post hoc with Bonferroni correction p < 0.008). (K) Longest
bridging axon beyond the graft, per subject. (Kruskall
Wallis test, c2 p < 0.003; Dunn post hoc with Bonferroni
correction p < 0.008) (L) Quantification of axon number
within graft demonstrates significantly greater axonal
penetration in subjects receiving full treatment (ANOVA
p < 0.01; post hoc Fisher’s *p < 0.01 comparing combina-
tion treatment to all other groups). Scale bar in (A), (C), and
(E), 200 mm; (B), (D), and (F), 50 mm; (G), (H), and (I),
200 mm. Data are shown as mean ± SEM.lesions alone, without CL, did not increase GAP43 or c-Jun.
cAMP levels in DRGs, measured 1 week after placement of
CLs, were also elevated equally when CLs were placed 6 weeks
after a central lesion or as pre-CLs (Figure 5F).
Next, we performed gene array analysis using Affymetrix
whole-genome chips in four groups of adult rats. Group 1
DRGs were harvested 1 week after CL (n = 9 animals, pooling
mRNA from three subjects, providing three arrays per group);
Group 2 DRGs were harvested 7 weeks after C3 spinal cord
lesion and 1 week after CL (i.e., CLs were placed 6 weeks after
SCI; n = 9 animals, three arrays); Group 3 DRGs were harvested
1 week after C3 lesion (no CL; n = 9, three arrays); and Group 4
DRGs were harvested 7 weeks after C3 lesion (no CL; n = 9,
degradation of pooled mRNA in one group resulted in two arrays
from six animals in this group). mRNA was also obtained from
DRGs of 12 intact animals (four arrays). Using a significance
criterion of 5% false discovery rate (FDR) and a log ratio greater
than 0.2 (15%), we found 5609 differentially expressed probes in
subjects that underwent CLs (Group 1) compared to intact
animals: of these, 2936 probes were upregulated and 2673
were downregulated (Figure 5Q). In marked contrast, no probes
changed at this level of significance in samples from animals with
C3 lesions only (no CL, Groups 3 and 4). Thus, peripheral, but not
central, lesions led to extensive and long-lasting changes in geneexpression. Notably, CLs performed 6 weeks after C3 lesions
also resulted in extensive changes in gene expression (6092
differentially expressed probes), and these changes overlapped
to an exceptionally high degree with those in animals that under-
went pre-CLs. Indeed, 4244 probes, corresponding to 76% of all
probes differentially expressed in animals that received pre-CLs,
were also differentially expressed in animals that underwent
post-CLs. Probes for GAP43 and c-Jun were elevated in
subjects with pre- and post-CLs (+85%–92% and +227%–
201% elevations, respectively, relative to controls), providing
independent confirmation of probe data. Functional annotation
identified, among others, modulation of transcriptional networks
centered around GAP43 and c-Jun in both groups with CLs,
whereas a C3 lesion had little effect on these pathways
(Figure S2).
DISCUSSION
These findings indicate that bridging axonal regeneration in
the adult CNS can be induced when experimental treatments
are administered at unprecedented delays of more than 1 year
after SCI. Regeneration after established injury requires
modification of both the intrinsic growth state of the neuron,
achieved by CLs, and modification of the nonpermissive injuryNeuron 64, 165–172, October 29, 2009 ª2009 Elsevier Inc. 169
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Regeneration of Chronically Injured AxonsFigure 5. Delayed CLs Increase Neuron-Intrinsic Growth Programs
(A–D) Lumbar DRG neurons were cultured onmyelin for 48 hr and labeled with NF200. Neurons from (A) naive controls extend shorter neurites than (B) CLs 1week
prior to isolation (pre-CL). (C) Dorsal column lesions 6 weeks prior to isolation have no influence on neurite extension, whereas (D) CLs applied 6 weeks following
C3 lesions (post-CL) significantly enhance neurite extension. Scale bar in (A)–(D), 80 mm. (E) Quantification of neurite outgrowth as mean percentage of control (A)
indicates that both pre-CL and post-CL significantly enhance neurite outgrowth on myelin compared to intact animals and animals that received only C3 lesions
(ANOVA p < 0.0001; post hoc Fisher’s *p < 0.0001). (F) Measurement of cAMP levels by ELISA 1 week after either pre- or post-CL demonstrated significant eleva-
tions over basal levels (ANOVA p < 0.003; post hoc Fisher’s *p < 0.001); C3 lesions alone have no effect. (G–K) Immunolabeling for GAP43 in lumbar DRG neurons
shows weak immunoreactivity in (G) DRGs from naive control animals. (H) Pre-CLs increase intensity and number of labeled neurons. (I) C3 lesions alone placed
6 weeks earlier do not increase GAP43 immunolabeling, whereas (J) post-CLs exhibit increased GAP43 labeling to the same degree that pre-CLs do. (K) Quan-
tification of the percentage of GAP43-labeled neurons reveals significant increase after pre- and post-CL (ANOVA p < 0.01; post hoc Fisher’s *p < 0.01). (L–P)
Immunolabeling for c-Jun in lumbar DRG neurons also shows few labeled nuclei in (L) naive control animals. (M) Pre-CL increases the number and intensity of
neurons labeled for c-Jun. (N) C3 lesions alone, 6 weeks earlier, do not increase c-Jun, whereas (O) post-CL 6 weeks after C3 lesions increases c-Jun labeling to
the same degree as in pre-CL. (P) Quantification shows significant increase in percentage of c-Jun-labeled neurons after pre- and post-CLs (ANOVA p < 0.003;
post hoc Fisher’s *p < 0.005). Scale bar in (G–J) and (L–O), 80 mm. (Q) Heatmap illustrating hierarchical clustering of gene expression from rat DRG extracted
1 week after pre- or post-CLs, or after C3 lesion alone. Comparisons in each case are made to intact DRGs. Red indicates increased, and green indicates
decreased, gene expression. Groups of samples are color coded. (Light green) Pre-CL upregulates more than 3000 probes over intact DRG. (Brown) Post-
CL persistently regulates, with similar intensity, a set of probes nearly identical to that of pre-CL. In contrast to gene changes observed after CL, a C3 central
lesion results in perturbation of remarkably fewer probe sets, whether gene changes are examined acutely after C3 lesion (purple) or 7 weeks after C3 injury
(pink). Data are shown as mean ± SEM.environment, accomplished by cell grafting and placement of
growth factor gradients beyond the lesion site. Manipulation of
the intrinsic neuronal growth state alone, or the environment
alone, is insufficient to support axonal bridging beyond the lesion.
Delayed conditioning of the injured neuron elicits modulation of
broad sets of genes remarkably similar in profile to those of CLs
placed before central injury, suggesting extensive recruitment of
intrinsicmolecularmechanisms that contribute to axonal regener-
ation. Thus, neuron-intrinsicmechanismsand the injuredenviron-170 Neuron 64, 165–172, October 29, 2009 ª2009 Elsevier Inc.ment can both be modified at extended delays after injury to
successfully elicit axonal bridging into, and beyond, sites of SCI.
Few studies have examined axonal regeneration when thera-
pies are administered at delays after injury, and most of these
have examined relatively brief delays of 1–8 weeks (Houle and
Tessler, 2003). Further, most delay treatment paradigms resect
the ‘‘chronic scar’’ (Coumans et al., 2001; Jin et al., 2000), risking
spinal cord reinjury (Tuszynski et al., 2003). Of these studies, only
one to our knowledge has reported axonal growth beyond the
Neuron
Regeneration of Chronically Injured Axonslesion, using a combination of a fetal spinal cord graft and growth
factors applied to a relesioned spinal cord 4 weeks after the orig-
inal injury (Coumans et al., 2001). The latter study reported
regeneration through both gray matter and inhibitory white
matter below the lesion resulting purely from cell-extrinsic exper-
imental manipulations within the lesion site; however, examples
of specific axons leaving the graft site were not provided. In con-
trast, axonal bridging in the present study is observed when
experimental therapies are provided at exceptionally prolonged
delays after the original injury, and only when both the intrinsic
neuronal growth state and the surrounding, inhibitory environ-
ment are modified, consistent with findings in acute injury
models (Lu et al., 2004). Relesioning the spinal cord was not
necessary to achieve axonal growth either into or beyond the
chronic lesion site in this study, enhancing clinical relevance: rel-
esioning the spinal cord risks further deterioration of function,
particularly in cervically injured subjects that are critically depen-
dent of neural systems spared immediately above the lesion site
to support residual function.
We examined a long-projecting axonal system, the dorsal
column sensory tract, as a model system because the projection
is well defined anatomically, it normally fails to regenerate after
central injury, and lesion completeness is readily verifiable by
examination of the gracilar target of this projection (Lu et al.,
2004; Taylor et al., 2006). Five observations suggest that axons
observed beyond the lesion actually regenerated, and were not
simply spared. First, the morphology of axons extending beyond
the lesion site was circuitous and their course was nonlinear,
unlike intact axons (Figures 1 and 3). Second, CTB-labeled
axons emerged across the lesion-host interface at different
dorsoventral levels of the graft, not simply the most ventral or
dorsal aspects of the graft/lesion site where spared axons might
be located (Figures 1, 2, 3, and 4). Third, CTB-labeled axons
were not observed ventral to the lesion site or in lateral, unle-
sioned portions of the spinal cord. Fourth, the lesion site was
devoid of GFAP immunoreactivity, which would otherwise be
present in strands of spared spinal cord parenchyma (Figure 4).
Fifth, sectioning of the medulla through the entire extent of the
nucleus gracilis revealed an absence of CTB-labeled axons in
all lesioned subjects, indicating that lesions were complete,
whereas dense labeling was readily detected in unlesioned
subjects (Figure S1). The latter observation also indicates that
axons did not regenerate over extended distances to reenter
the denervated nucleus.
Having established that bridging axonal regeneration is
feasible in the sensory model at remarkably extended delays
after injury, findings can be adapted to descendingmotor projec-
tions of the spinal cord. While pools of axons recruitable for
regeneration persist at prolonged time points postinjury, the
number of sensory axons regenerating beyond the lesion site
is lower when therapy is applied 15 months postinjury compared
to 6 weeks postinjury, and the distance that axons regenerate
beyond the lesion is also reduced after prolonged treatment
times (Figures 2 and 4). For these reasons, attempts to achieve
chronic functional recovery should likely target cervical-level
lesions, because potential neuronal targets of regenerating
axons can be contacted immediately below the lesion site. If
reinnervation of denervated motor neuron pools even one levelbelow a lesion were achieved, the impact on quality of life in
spinal-cord-injured subjects could be substantial, potentially
providingmovement of awrist or hand that could support greater
independence. Incremental improvements in function are amore
tractable goal for human translation, andmay be achievable with
rational, safe therapies that target neuron-intrinsic and environ-
mental mechanisms.
EXPERIMENTAL PROCEDURES
For additional Experimental Procedures, see the Supplemental Data.
Surgery and Tissue Processing
Female Fisher 344 rats (n = 182) weighing 160–200 g were experimental
subjects. C3 dorsal columns were completely transected bilaterally using
a tungsten wire knife (Lu et al., 2004). Peripheral CLs were made by firm
compression of the exposed nerve at midthigh level using jeweler’s forceps
for 15 s. MSCs were isolated as described previously (Azizi et al., 1998). The
chronic lesion site was re-exposed and 2 ml (75,000 cells/ml) of passage 4
MSCs, mixed with fibrin glue, were grafted into the lesion cavity. Lenti-NT-3
vector and lenti-GFP vector were generated as previously described (Taylor
et al., 2006) and 2.5 ml was injected 2.5 mm rostral to the lesion site in dorsal
column white matter (titer 100 mg/ml p24, 1x108 Infectious Units/ml).
Dorsal-column sensory axons were labeled transganglionically by CTB injec-
tion into the sciatic nerve proximal to the CL site (2 ml, 1% solution) 3 days
before perfusion. Animals were perfused with 4% PFA and subjected to
CTB, GFP, and GFAP immunocytochemistry on 30 mm thick spinal cord
sections.
Axonal Quantification
Axon number was quantified in 1-in-6 sections within and beyond the lesion
site. Lesion margins were determined using GFAP immunoreactivity (Taylor
et al., 2006), and axons crossing a vertical line placed in sagittal sections within
the graft midpoint, and 0, 50, 100, 250, 500, 1000, 2000, and 2500 mm rostral to
the rostral lesion border, were counted. Total axon number/subject was calcu-
lated by multiplying the counted number by 6. The longest distance of regen-
erating axons from the rostral lesion border was also measured. Observers
were blinded to group identity.
DRG Isolation, Culture, and Labeling
Dissected adult L4–6 DRGs were digested for 1 hr in 0.25% collagenase type
XI, triturated, and resuspended on 35 mm cell culture dishes coated with
myelin (18 mg/ml per well). Cells were fixed 48 hr later with 4%PFA and labeled
for NF200. Longest neurite length/cell was measured from a minimum of
150 cells/animal (n = 4 DRGs/group). Thirty-five-micometer sections of L4–6
adult DRG were immunolabeled for GAP43 and c-Jun and counterstained
with Hoechst 33342. The percentage of GAP43- or c-Jun-labeled neurons
was quantified as described(n = 3 DRGs/group, Qiu et al., 2005).
cAMP ELISA
L4–6 DRGs were dissected, homogenized, and subjected to cAMP ELISA
(Assay designs; n = 7 DRGs/group).
Array Methods
L4–6 DRGs were dissected, frozen at 80C, and RNA extracted. RNA
samples were reverse transcribed and labeled per the manufacturer’s instruc-
tions, and hybridized to Affymetrix high-density oligonucleotide GeneChip Rat
Genome 230 2.0 Arrays (Affymetrix).
Statistical Analysis
All experiments and analyses were conducted under blinded conditions.
Quantification of axon number beyond lesion sites and axonal length was
assessed by Kruskall Wallis followed by Dunn post hoc and Bonferroni adjust-
ment. In all other quantifications, multiple group comparisons were made byNeuron 64, 165–172, October 29, 2009 ª2009 Elsevier Inc. 171
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Regeneration of Chronically Injured AxonsANOVA, with post hoc Fisher’s. A significance criterion of p < 0.05 was used.
Data are presented as mean ± SEM.
SUPPLEMENTAL DATA
Supplemental data for this article include Supplemental Experimental Proce-
dures and two figures and can be found at http://www.cell.com/neuron/
supplemental/S0896-6273(09)00698-9.
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